Reporte zur Charge IR8731

Symptomtext

New onset seizure activity diagnosed in month of July while patient at home with family.; EEG demonstrated "focal" seizure activity.; This is a spontaneous report from a contactable physician. A 85-year-old female patient received bnt162b2 (Pfizer-BioNTech COVID-19 Vaccine, solution for injection, Batch/Lot Number: IR8731)via intramuscular, route of administration, administered in left arm on 01Apr2021 at 10:00 as Dose 1,Single for COVID-19 immunization. Medical history included high blood pressure, a fib (Atrial fibrillation), high cholesterol, TVAR (Transcatheter aortic valve implantation), hx CHF (cardiac failure congestive), seizures and anxiety from an unknown date and unknown if ongoing. Concomitant medications included metoprolol (METOPROLOL), diltiazem hydrochloride (CARDIAZEM (AVENTIS)), rosuvastatin calcium (CRESTOR), celecoxib (CELEXA [CELECOXIB]), furosemide (LASIX [FUROSEMIDE]), potassium chloride (POTASSIUM CHLORIDE) and apixaban (ELIQUIS) taken for an unspecified indication, start and stop date were not reported. The patient previously took Bactrim and flourecin contrast and experienced known allergies for bactrim and flourecin contrast. The patient experienced new onset seizure activity diagnosed in month of july while patient at home with family and EEG demonstrated focal seizure activity on 06Jul2021 at 19:00. The patient received treatment for the events. The patient was hospitalized for eeg demonstrated focal seizure activity (partial seizures) for 5 days. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. The patient was not tested positive for covid 19 prior to vaccination and had not been tested post vaccination. The outcome of the events was unknown.